Drug intelligence / Profile preview

CTAP

Development stage: Unknown
Modality: Peptides
Administration: Intracerebroventricular, Subcutaneous

Overview

CTAP is a **potent and selective mu-opioid receptor antagonist peptide**, structurally an analogue of somatostatin. It exhibits high specificity for blockade of the **mu-opioid receptor** with minimal activity at delta-opioid and somatostatin receptors, enabling researchers to selectively inhibit mu-opioid-mediated effects in vivo and in vitro. It crosses the blood–brain barrier, making it suitable for central nervous system studies involving opioid pathways. CTAP is intended for laboratory research use and is not approved as a marketed pharmaceutical for medical use in humans[1][2].

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on CTAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTAP.

Explore the full profile